+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

MRNA Synthesis Raw Materials Market Outlook 2026-2034: by Application (Vaccines, Therapeutics, Research & Diagnostics), Raw Material Type, Purity Grade, End User

  • PDF Icon

    Report

  • 160 Pages
  • October 2026
  • Region: Global
  • OG Analysis
  • ID: 6242073
UP TO OFF until Jan 01st 2027
The MRNA Synthesis Raw Materials Market is estimated at US$2.1 billion in 2026 and is projected to grow at a CAGR of 6.1% to reach US$3.4 billion by 2034.

Market Overview

The MRNA Synthesis Raw Materials Market covers critical inputs used in messenger ribonucleic acid synthesis workflows including nucleotides, enzymes, caps, templates, lipids, and related formulation materials. Its value chain spans suppliers, manufacturers, service partners, channels, and users across vaccine development, therapeutic discovery, clinical manufacturing, research laboratories, and advanced biologics production programs.

Current direction reflects higher purity inputs, supply redundancy, traceable sourcing, and stronger alignment with scalable therapeutic and vaccine manufacturing requirements. Competition includes life science input suppliers, specialized raw material producers, contract manufacturing partners, and biotechnology reagent companies, with differentiation tied to reliability, usability, technical depth, and support quality.

Market Segmentation

By Application

  • Vaccines
  • Therapeutics
  • Research & Diagnostics

By Raw Material Type

  • Modified Nucleotides
  • Unmodified Nucleotides
  • Cap Analogs & Capping Reagents
  • RNA Polymerase & Auxiliary Enzymes
  • Plasmid DNA Templates
  • Buffers & Reagents
  • Lipid Nanoparticle Components

By Purity Grade

  • Research Grade
  • GMP Grade

By End User

  • Biopharmaceutical & Biotech Companies
  • CDMOs & CROs
  • Academic & Research Institutes

Key Companies Analysed

  • Thermo Fisher Scientific
  • Merck KGaA
  • TriLink BioTechnologies
  • Maravai LifeSciences
  • Cytiva
  • Danaher
  • Aldevron
  • Promega
  • New England Biolabs
  • Agilent Technologies
  • BioNTech
  • Moderna
  • AstraZeneca
  • ReciBioPharm
  • Nitto Avecia
  • Sartorius
  • BASF
  • Wacker Chemie
  • Evonik
  • Lonza

Geographic Coverage

  • North America - Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Poland
    • Sweden
    • Russia

  • Asia-Pacific - Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

  • Updated PDF report and an MS Excel workbook containing market tables and figures.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data.
  • Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Contents and Report Guide
1.1. List of Tables
1.2. List of Figures
2. Global MRNA Synthesis Raw Materials Market Overview
2.1. MRNA Synthesis Raw Materials Market Scope and Definitions
2.2. Research Methodology and Forecast Assumptions
2.3. Value Chain and Relevant Adjacent Markets
3. MRNA Synthesis Raw Materials Market Dynamics
3.1. Demand Drivers
3.2. Constraints and Adoption Barriers
3.3. Technology and Commercial Trends
3.4. Regulatory and Supply-Chain Considerations
4. MRNA Synthesis Raw Materials Market Strategic Analysis
4.1. Competitive Structure
4.2. Pricing and Purchasing Factors
4.3. Customer Requirements and Opportunity Assessment
5. Global MRNA Synthesis Raw Materials Market Size, Share and Forecast, 2025-2034
5.1. Revenue Outlook, 2025-2034 (US$ billion)
5.2. MRNA Synthesis Raw Materials Market Analysis By Application, 2025-2034
5.2.1. Vaccines
5.2.2. Therapeutics
5.2.3. Research & Diagnostics
5.3. MRNA Synthesis Raw Materials Market Analysis By Raw Material Type, 2025-2034
5.3.1. Modified Nucleotides
5.3.2. Unmodified Nucleotides
5.3.3. Cap Analogs & Capping Reagents
5.3.4. RNA Polymerase & Auxiliary Enzymes
5.3.5. Plasmid DNA Templates
5.3.6. Buffers & Reagents
5.3.7. Lipid Nanoparticle Components
5.4. MRNA Synthesis Raw Materials Market Analysis By Purity Grade, 2025-2034
5.4.1. Research Grade
5.4.2. GMP Grade
5.5. MRNA Synthesis Raw Materials Market Analysis By End User, 2025-2034
5.5.1. Biopharmaceutical & Biotech Companies
5.5.2. CDMOs & CROs
5.5.3. Academic & Research Institutes
6. North America MRNA Synthesis Raw Materials Market Outlook to 2034
6.1. North America Market Snapshot
6.2. North America MRNA Synthesis Raw Materials Market Analysis By Application
6.3. North America MRNA Synthesis Raw Materials Market Analysis By Raw Material Type
6.4. North America MRNA Synthesis Raw Materials Market Analysis By Purity Grade
6.5. North America MRNA Synthesis Raw Materials Market Analysis By End User
6.6. North America Outlook By Country
6.6.1. United States
6.6.2. Canada
6.6.3. Mexico
7. Europe MRNA Synthesis Raw Materials Market Outlook to 2034
7.1. Europe Market Snapshot
7.2. Europe MRNA Synthesis Raw Materials Market Analysis By Application
7.3. Europe MRNA Synthesis Raw Materials Market Analysis By Raw Material Type
7.4. Europe MRNA Synthesis Raw Materials Market Analysis By Purity Grade
7.5. Europe MRNA Synthesis Raw Materials Market Analysis By End User
7.6. Europe Outlook By Country
7.6.1. Germany
7.6.2. United Kingdom
7.6.3. France
7.6.4. Italy
7.6.5. Spain
7.6.6. Netherlands
7.6.7. Switzerland
7.6.8. Poland
7.6.9. Sweden
7.6.10. Russia
8. Asia-Pacific MRNA Synthesis Raw Materials Market Outlook to 2034
8.1. Asia-Pacific Market Snapshot
8.2. Asia-Pacific MRNA Synthesis Raw Materials Market Analysis By Application
8.3. Asia-Pacific MRNA Synthesis Raw Materials Market Analysis By Raw Material Type
8.4. Asia-Pacific MRNA Synthesis Raw Materials Market Analysis By Purity Grade
8.5. Asia-Pacific MRNA Synthesis Raw Materials Market Analysis By End User
8.6. Asia-Pacific Outlook By Country
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Australia
8.6.6. Indonesia
8.6.7. Malaysia
8.6.8. Vietnam
9. Middle East and Africa MRNA Synthesis Raw Materials Market Outlook to 2034
9.1. Middle East and Africa Market Snapshot
9.2. Middle East and Africa MRNA Synthesis Raw Materials Market Analysis By Application
9.3. Middle East and Africa MRNA Synthesis Raw Materials Market Analysis By Raw Material Type
9.4. Middle East and Africa MRNA Synthesis Raw Materials Market Analysis By Purity Grade
9.5. Middle East and Africa MRNA Synthesis Raw Materials Market Analysis By End User
9.6. Middle East and Africa Outlook By Country
9.6.1. Saudi Arabia
9.6.2. South Africa
9.6.3. Iran
9.6.4. United Arab Emirates
9.6.5. Egypt
10. South and Central America MRNA Synthesis Raw Materials Market Outlook to 2034
10.1. South and Central America Market Snapshot
10.2. South and Central America MRNA Synthesis Raw Materials Market Analysis By Application
10.3. South and Central America MRNA Synthesis Raw Materials Market Analysis By Raw Material Type
10.4. South and Central America MRNA Synthesis Raw Materials Market Analysis By Purity Grade
10.5. South and Central America MRNA Synthesis Raw Materials Market Analysis By End User
10.6. South and Central America Outlook By Country
10.6.1. Brazil
10.6.2. Argentina
10.6.3. Chile
10.6.4. Peru
11. MRNA Synthesis Raw Materials Market Competitive Landscape
11.1. Market Participants and Strategic Positioning
11.2. Company Profiles: Product Portfolios, Positioning and Strategies
11.2.1. Thermo Fisher Scientific
11.2.2. Merck KGaA
11.2.3. TriLink BioTechnologies
11.2.4. Maravai LifeSciences
11.2.5. Cytiva
11.2.6. Danaher
11.2.7. Aldevron
11.2.8. Promega
11.2.9. New England Biolabs
11.2.10. Agilent Technologies
11.2.11. BioNTech
11.2.12. Moderna
11.2.13. AstraZeneca
11.2.14. ReciBioPharm
11.2.15. Nitto Avecia
11.2.16. Sartorius
11.2.17. BASF
11.2.18. Wacker Chemie
11.2.19. Evonik
11.2.20. Lonza
12. Appendix
12.1. Definitions and Abbreviations
12.2. Data Sources and Methodology
12.3. Publisher Information

Companies Mentioned

  • Thermo Fisher Scientific
  • Merck KGaA
  • TriLink BioTechnologies
  • Maravai LifeSciences
  • Cytiva
  • Danaher
  • Aldevron
  • Promega
  • New England Biolabs
  • Agilent Technologies
  • BioNTech
  • Moderna
  • AstraZeneca
  • ReciBioPharm
  • Nitto Avecia
  • Sartorius
  • BASF
  • Wacker Chemie
  • Evonik
  • Lonza

Table Information